Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Provided By GlobeNewswire
Last update: Oct 10, 2024
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC)
Lilly leads the clinical development of the Phase 1 trial
Read more at globenewswire.com
